Drug discovery in the next millennium

被引：79

作者：

Ohlstein, EH ^{[1
]}

Ruffolo, RR

Elliott, JD

机构：

[1] SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, Res & Dev, King Of Prussia, PA 19406 USA

[2] SmithKline Beecham Pharmaceut, Dept Med Chem, Res & Dev, King Of Prussia, PA 19406 USA

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2000年 / 40卷

关键词：

target validation; functional genomics; proteomics; high-throughput screening; combinatorial chemistry; cheminformatics; gene therapy;

D O I：

10.1146/annurev.pharmtox.40.1.177

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Selection and validation of novel molecular targets have become of paramount importance in light of the plethora of new potential therapeutic drug targets that have emerged from human gene sequencing. In response to this revolution within the pharmaceutical industry, the development of high-throughput methods in both biology and chemistry has been necessitated. This review addresses these technological advances as well as several new areas that have been created by necessity to deal with this new paradigm, such as bioinformatics, cheminformatics, and functional genomics. With many of these key components of future drug discovery now in place, it is possible to map out a critical path for this process that will be used into the new millennium.

引用

页码：177 / 191

页数：15

共 39 条

[1] Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].

Ames, RS ;

Sarau, HM ;

Chambers, JK ;

Willette, RN ;

Alyar, NV ;

Romanic, AM ;

Louden, CS ;

Foley, JJ ;

Sauermelch, CF ;

Coatney, RW ;

Ao, ZH ;

Disa, J ;

Holmes, SD ;

Stadel, JM ;

Martin, JD ;

Liu, WS ;

Glover, GI ;

Wilson, S ;

McNulty, DE ;

Ellis, CE ;

Elshourbagy, NA ;

Shabon, U ;

Trill, JJ ;

Hay, DWP ;

Ohlstein, EH ;

Bergsma, DJ ;

Douglas, SA .

NATURE, 1999, 401 (6750) :282-286

[2] Proteomics: quantitative and physical mapping of cellular proteins [J].

Blackstock, WP ;

Weir, MP .

TRENDS IN BIOTECHNOLOGY, 1999, 17 (03) :121-127

[3] Selective detection and sequencing of phosphopeptides at the femtomole level by mass spectrometry [J].

Carr, SA ;

Huddleston, MJ ;

Annan, RS .

ANALYTICAL BIOCHEMISTRY, 1996, 239 (02) :180-192

[4] A HOT-SPOT OF BINDING-ENERGY IN A HORMONE-RECEPTOR INTERFACE [J].

CLACKSON, T ;

WELLS, JA .

SCIENCE, 1995, 267 (5196) :383-386

[5] The impact of genomics on drug discovery [J].

Debouck, C ;

Metcalf, B .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2000, 40 :193-207

[6] Use of X-ray co-crystal structures and molecular modeling to design potent and selective non-peptide inhibitors of cathepsin K [J].

DesJarlais, RL ;

Yamashita, DS ;

Oh, HJ ;

Uzinskas, IN ;

Erhard, KF ;

Allen, AC ;

Haltiwanger, RC ;

Zhao, BG ;

Smith, WW ;

Abdel-Meguid, SS ;

D'Alessio, K ;

Janson, CA ;

McQueney, MS ;

Tomaszek, TA ;

Levy, MA ;

Veber, DF .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1998, 120 (35) :9114-9115

[7] DISCOVERY OF A NOVEL SERIES OF ORALLY-ACTIVE NONPEPTIDE ENDOTHELIN-A (ET(A)) RECEPTOR-SELECTIVE ANTAGONISTS [J].

DOHERTY, AM ;

PATT, WC ;

EDMUNDS, JJ ;

BERRYMAN, KA ;

REISDORPH, BR ;

PLUMMER, MS ;

SHAHRIPOUR, A ;

LEE, C ;

CHENG, XM ;

WALKER, DM ;

HALEEN, SJ ;

KEISER, JA ;

FLYNN, MA ;

WELCH, KM ;

HALLAK, H ;

TAYLOR, DG ;

REYNOLDS, EE .

JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (08) :1259-1263

[8]

Eyermann CJ, 1997, ADV AMIN AC MIM PEPT, V1, P1

[9]

GRISWOLD DE, 1999, IN PRESS MOL PHARM

[10] Clinical evidence of angiogenesis after arterial gene transfer of phVEGF(165) in patient with ischaemic limb [J].

Isner, JM ;

Pieczek, A ;

Schainfeld, R ;

Blair, R ;

Haley, L ;

Asahara, T ;

Rosenfield, K ;

Razvi, S ;

Walsh, E ;

Symes, JF .

LANCET, 1996, 348 (9024) :370-374

← 1 2 3 4 →